ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ravi Madan discussing preliminary data from 6 month follow-up assessing prospective monitoring of PSMA–positive ...

The score ranges from 6 to 10 because grades 1 and 2 are rarely used for cancer diagnosis. (a score of 1-2 means that you do not have cancer) A lower ...

Johnson & Johnson (NYSE:JNJ) said on Tuesday that niraparib, a cancer treatment from a group of drugs called PARP inhibitors, ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Prostate cancer remains the most common cancer in men and the second deadliest. The median age of diagnosis is 67. Yet, ...

Daniel J. Stone Former President Joe Biden’s metastatic cancer diagnosis brings together two controversial issues: PSA testing for prostate cancer and presidential politics.  To understand what is at ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

Dr. Alan Bryce presented the preliminary results from a phase II trial of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Late-line mCRPC patients have poor ...

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer ...